CYTOSORBENTS MEDICAL INC — Department of Defense SBIR: AWARD OF CYTOSORBENTS DHA SBIR PH III MED R&D CONTRACT FOR "INTEGRATING ISOAGGLUTININ REDU
CYTOSORBENTS MEDICAL INC — SBIR award from Department of Defense.
SBIR award competitive context
- Public SBIR obligation from Department of Defense to CYTOSORBENTS MEDICAL INC. Use agency + tech-domain links below to map the broader competitive field.
- At $4,292,641, this is a large obligation for typical SBIR Phase sizing — worth reviewing for scope breadth and teaming opportunity.
- Tagged technology areas: Human Performance & Medical. Follow those hubs for open topics and peer winners in the same cluster.
Summary
Cytosorbents Medical Inc received over $4.2 million from the Department of Defense to develop a universal dried plasma product for battlefield and emergency use. The project focuses on reducing isoagglutinins to make the plasma compatible with all blood types.
- Amount
- $4,292,641
- Agency
- Department of Defense · Defense Health Agency
- Program / Phase
- SBIR
- NAICS
- 541715 · RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)
- Place of performance
- NJ
- Period
- 2022-08-22 → 2026-12-21
Technology domains
Description
AWARD OF CYTOSORBENTS DHA SBIR PH III MED R&D CONTRACT FOR "INTEGRATING ISOAGGLUTININ REDUCTION FOR A UNIVERSAL DRIED PLASMA PRODUCT FOR BATTLEFIELD AND FIRST RESPONDER USE"